An observational study in Takotsubo Cardiomyopathy, Broken Heart Syndrome and Tako-tsubo Cardiomyopathy, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by NYU Langone Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Takotsubo Cardiomyopathy with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Takotsubo Cardiomyopathy · United States.
Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, this one is one of 2 that started in 2009, is one of 5 observational ones, and was the 7th registered.
63 studies on the registry are indexed under Takotsubo Cardiomyopathy; 26 are open to participants now.
Browse Takotsubo Cardiomyopathy studies →3 of the 11 studies in Takotsubo Cardiomyopathy with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Takotsubo Cardiomyopathy studies recruiting now, 19 (83%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2009.
This study's planned enrollment of 500 is above the median of 250 across 39 observational studies indexed under Takotsubo Cardiomyopathy.
Median enrollment 17 across the 6 interventional studies, 190 across the 5 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 8 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 2 studies filed under Takotsubo Cardiomyopathy — fewer than ten, so there is no comparison to draw.
1 of the studies in Takotsubo Cardiomyopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03324529NYU Langone HealthAutonomic Modulation in Takotsubo Syndrome | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Takotsubo syndrome is a condition which mimics acute myocardial infarction, and is diagnosed in 1.5% to 2.2% of patients referred to hospital with suspected acute coronary syndrome. It is also known as broken heart syndrome, takotsubo cardiomyopathy, stress cardiomyopathy and apical ballooning cardiomyopathy, among other names. The pathogenesis of this disorder is not well understood. Possible mechanisms include catecholamine excess, coronary artery spasm, microvascular dysfunction, among others. This is a multicenter, nation-wide, observational study of patients who were previously diagnosed with takotsubo syndrome. The investigators aim to use this registry to help plan and carry out further studies and to improve understanding of the pathophysiologic mechanisms of this syndrome. In addition participants will be followed for events, and to monitor quality of life and stress.
Patients are eligible to participate if they are aged 18 years or older and carry a physician confirmed diagnosis of takotsubo syndrome. Patients with a history of takotsubo syndrome will be identified via physician referral, Epic search and patient self-referral. Patients may register directly through our registry website at www.nyulmc.org/brokenheartstudy or via direct contact with the study team via e-mail or telephone. Following completion of a research authorization form and collection of medical records, study team will confirm the diagnosis of takotsubo syndrome. Data will be collected including contact information, medical history, data on the takotsubo event(s) including physician records and all relevant imaging. Participants will also be asked quality of life questionnaires and will be followed every 4 months for events.
Patients with history of takotsubo syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Lack of capacity to provide
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Major Adverse Cardiac Events
Medical record review and patient report of repeat takotsubo event, MI, heart failure, unstable angina, chest pain ER visit, cardiovascular death, stroke
Time frame: up to 10 years
Quality of life assessed using the Patient Reported Outcome Measurement Information System (PROMIS-10) questionnaire
Measure of quality of life
Time frame: every four months up to 10 years
Anxiety is assessed using the Hospital Anxiety and Depression Scale (HADS-A)
Measure of anxiety
Time frame: every four months up to 10 years
Depression assessed using the Patient Health Questionnaire (PHQ-9)
Measure of depression
Time frame: every four months up to 10 years
Perceived stress is measured using the Perceived Stress Scale (PSS-10)
Measure of perceived stress
Time frame: every four months up to 10 years
Started Sep 2009 (actual). Primary completion is estimated for Sep 2028, 227 months after the start.
Of 25 observational studies under Takotsubo Cardiomyopathy, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 40. This study's planned 227 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.